4-硼-3-甲基苯甲酸 | 158429-66-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-硼-3-甲基苯甲酸
• 中文别名: (2-甲基-4-羧基苯基)硼酸；(2甲基4羧基苯基)硼酸；(2-甲基4-羧基苯基)硼酸；(2 - 甲基4 - 羧基苯基)硼酸
• 英文名称: 4-borono-3-methylbenzoic acid
• CAS: 158429-66-4
• 化学式: C₈H₉BO₄
• mdl: MFCD09037833
• 分子量: 179.968
• InChiKey: QIGSMEYLQVLGRY-UHFFFAOYSA-N

物化性质

• 沸点：
  409.2±55.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8℃，干燥，密闭。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-Carboxy-2-methylphenylboronic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-Carboxy-2-methylphenylboronic acid
CAS number: 158429-66-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H9BO4
Molecular weight: 180.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-硼-3-甲基苯甲酸 在 硫酸 作用下， 以 甲苯 为溶剂， 反应 36.0h， 生成
  参考文献：
  名称：

  模块化固相合成方法可优化寡硼酸受体和传感器的结构和电子性能，以进行寡糖的水相识别。

  摘要：

  本文介绍了第一种完全模块化，平行固相合成方法的设计和优化，该方法用于生成定义明确的多胺寡硼酸受体和复杂寡糖的荧光传感器。合成方法允许有效构建受体多胺主链，然后控制胺苄基侧链的多样化。这种方法能够以模块化的方式测试被无阻碍的对位吸电子基团或供电子基团取代的不同芳基硼酸单元的作用。还通过使用Irori MiniKan技术组装受体子库，研究了这种自动合成方法的可行性。合成了包含两个或三个芳基硼酸的蒽封端的传感器的几个子库，并在中性水性介质中检查了它们与一系列模型二糖的结合。通过荧光滴定法对缔合常数的计算证实，聚胺主链中胺间间隔基结构的细微变化可对所得配合物的稳定性产生重大影响。最重要的是，这项研究导致确定了芳基硼酸酯单元的首选电子特性，并暗示了新一代的含有非常贫电子的芳基硼酸的受体可能会导致结合亲和力的显着改善。通过荧光滴定法对缔合常数的计算证实，聚胺主链中胺间间隔基结构的细微变化可对所得配合物

  DOI：

  10.1002/chem.200305400
• 作为产物：
  描述：

  3-甲基-4-溴苯甲酸 在 盐酸 、 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 6.5h， 生成 4-硼-3-甲基苯甲酸
  参考文献：
  名称：

  模块化固相合成方法可优化寡硼酸受体和传感器的结构和电子性能，以进行寡糖的水相识别。

  摘要：

  本文介绍了第一种完全模块化，平行固相合成方法的设计和优化，该方法用于生成定义明确的多胺寡硼酸受体和复杂寡糖的荧光传感器。合成方法允许有效构建受体多胺主链，然后控制胺苄基侧链的多样化。这种方法能够以模块化的方式测试被无阻碍的对位吸电子基团或供电子基团取代的不同芳基硼酸单元的作用。还通过使用Irori MiniKan技术组装受体子库，研究了这种自动合成方法的可行性。合成了包含两个或三个芳基硼酸的蒽封端的传感器的几个子库，并在中性水性介质中检查了它们与一系列模型二糖的结合。通过荧光滴定法对缔合常数的计算证实，聚胺主链中胺间间隔基结构的细微变化可对所得配合物的稳定性产生重大影响。最重要的是，这项研究导致确定了芳基硼酸酯单元的首选电子特性，并暗示了新一代的含有非常贫电子的芳基硼酸的受体可能会导致结合亲和力的显着改善。通过荧光滴定法对缔合常数的计算证实，聚胺主链中胺间间隔基结构的细微变化可对所得配合物

  DOI：

  10.1002/chem.200305400

文献信息

• [EN] BCR-ABL TYROSINE-KINASE LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME<br/>[FR] LIGANDS DE TYROSINE-KINASE BCR-ABL CAPABLES DE SE DIMÉRISER DANS UNE SOLUTION AQUEUSE, ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：COFERON INC

  公开号：WO2015106292A1

  公开（公告）日：2015-07-16

  Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g. invivo) to form a multimer (e.g. a dimer). Contemplated monomers may include a ligand moiety, a linker element, and a connector element that joins the ligand moiety and the linker element. In an aqueous media, such contemplated monomers may join together via each linker element and may thus be capable of modulating one or more biomolecules substantially simultaneously, e.g., modulate two or more binding sites on a Bcr-Abl tyrosine kinase.

  本文描述了一种单体，当与水性介质中的另一个、两个、三个或更多其他单体接触时，能够形成生物学上有用的多聚体。在一个方面，这种单体可能能够在水性介质（例如体内）中与另一个单体结合以形成多聚体（例如二聚体）。考虑到的单体可能包括配体基团、连接元素和连接配体基团与连接元素的连接元素。在水性介质中，这些考虑到的单体可以通过每个连接元素结合在一起，因此可以同时调节一个或多个生物分子，例如，调节Bcr-Abl酪氨酸激酶上的两个或更多结合位点。
• C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors
  作者：Zheng Liu、Jacob J. Swidorski、Beata Nowicka-Sans、Brian Terry、Tricia Protack、Zeyu Lin、Himadri Samanta、Sharon Zhang、Zhufang Li、Dawn D. Parker、Sandhya Rahematpura、Susan Jenkins、Brett R. Beno、Mark Krystal、Nicholas A. Meanwell、Ira B. Dicker、Alicia Regueiro-Ren

  DOI：10.1016/j.bmc.2016.03.001

  日期：2016.4

  A series of C-3 phenyl- and heterocycle-substituted derivatives of C-3 deoxybetulinic acid and C-3 deoxybetulin was designed and synthesized as HIV-1 maturation inhibitors (MIs) and evaluated for their antiviral activity and cytotoxicity in cell culture. A 4-subsituted benzoic acid moiety was identified as an advantageous replacement for the 3′3′-dimethylsuccinate moiety present in previously disclosed

  设计并合成了一系列C-3脱氧贝丁酸和C-3脱氧贝丁酸的C-3苯基和杂环取代衍生物，作为HIV-1成熟抑制剂（MIs），并评估了它们在细胞培养中的抗病毒活性和细胞毒性。鉴定出4-取代的苯甲酸部分是先前公开的MI中存在的3'3'-二甲基琥珀酸酯部分的有利替代物，其阐明了药效团的拓扑学的新方面。与原型HIV-1 MI bevirimat（1，BVM）相比，新的类似物对野生型（wt）病毒具有出色的体外抗病毒活性，并且血清转移降低，这是临床研究中第一个评估的MI。化合物9a对wt病毒表现出与1类似的细胞培养能力（ 对于9a， WT EC 50 = 16 nM，而对于1a，则为10 nM ）。但是，9a的效力受人血清的影响较小，而该化合物在大鼠中的药代动力学特征与1相似。因此，9a（脱氧贝丁酸的4-苯甲酸衍生物）代表了探索第二代MI设计的新起点。
• [EN] AMINOQUINOLINE DERIVATIVES AS ANTIVIRAL AGENTS<br/>[FR] DÉRIVÉS D'AMINOQUINOLÉINE COMME AGENTS ANTIVIRAUX
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2012037108A1

  公开（公告）日：2012-03-22

  Provided are compounds of Formula (I) and Formula (II) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections mediated by a member of the Flaviviridae family of viruses such as hepatitis C virus (HCV).

  提供的是式(I)和式(II)的化合物及其药用盐，它们的药物组合物，它们的制备方法，以及它们用于治疗由黄病毒科病毒介导的病毒感染，如丙型肝炎病毒（HCV）。
• [EN] IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT HYPERPROLIFERATIVE DISORDERS<br/>[FR] IMIDAZOPYRAZINES POUR L'UTILISATION EN TANT QU'INHIBITEURS DE MPS-1 ET DE TKK DANS LE TRAITEMENT DE TROUBLES D'HYPERPROLIFÉRATION
  申请人：BAYER PHARMA AG

  公开号：WO2012080229A1

  公开（公告）日：2012-06-21

  The present invention relates to substituted imidazopyrazine compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

  本发明涉及通式(I)的取代咪唑吡嗪化合物，其中R1、R2、R3、R4和R5如权利要求中所定义，以及制备所述化合物的方法和中间体，包括所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是用作唯一药剂或与其他活性成分组合使用，治疗或预防过度增殖和/或血管生成障碍。
• [EN] SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES<br/>[FR] 1,3,8-TRIAZASPIRO[4,5]DÉCANE-2,4-DIONES SUBSTITUÉES
  申请人：MERCK SHARP & DOHME

  公开号：WO2010147776A1

  公开（公告）日：2010-12-23

  The present invention relates to substituted 1,3,8-triazaspiro[4.5]decame-2,4-diones useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

  本发明涉及替代的1,3,8-三氮杂螺[4.5]癸烯-2,4-二酮，可用作HIF脯氨酸羟化酶抑制剂，用于治疗贫血和类似症状。